Illumina, Inc. (NASDAQ:ILMN) Stock Has Average Target Price of $238.53 According to Analysts

Illumina, Inc. (NASDAQ:ILMN) has received a consensus recommendation of “Hold” from the nineteen brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $244.24.

A number of analysts have weighed in on ILMN shares. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. TD Cowen lifted their price objective on Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and boosted their target price for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Canaccord Genuity Group boosted their target price on shares of Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, October 19th. Finally, Piper Sandler upped their target price on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, September 28th.

Illumina Stock Down 8.2%

Shares of ILMN opened at $208.00 on Friday. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $249.44 and a two-hundred day moving average price of $177.79. The stock has a market cap of $31.45 billion, a price-to-earnings ratio of 43.15, a P/E/G ratio of 3.08 and a beta of 1.46. Illumina has a 12 month low of $112.65 and a 12 month high of $309.35.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the company posted $1.34 EPS. The company’s revenue was up 4.2% compared to the same quarter last year. Equities analysts predict that Illumina will post 5.43 EPS for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 299,336 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the transaction, the director directly owned 1,409,851 shares in the company, valued at $307,291,123.96. The trade was a 17.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders have sold 1,601,541 shares of company stock worth $354,755,291. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Illumina in the second quarter valued at approximately $3,374,423,000. WCM Investment Management LLC raised its holdings in Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Primecap Management Co. CA acquired a new stake in Illumina in the second quarter worth $617,981,000. Ninety One UK Ltd raised its holdings in Illumina by 37,920.0% in the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after purchasing an additional 1,356,397 shares during the period. Finally, Jupiter Topco LLC bought a new position in shares of Illumina during the second quarter worth $358,652,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.